Literature DB >> 20735317

Animal models of osteosarcoma.

Timothy M Fan1.   

Abstract

Appendicular osteosarcoma (OS) is a primary mesenchymal tumor arising from malignantly transformed osteoblasts. In people, OS is the most common nonhematopoietic, primary skeletal neoplasm diagnosed in adolescents and is the second leading cause of cancer-related fatalities within this age group. Despite aggressive therapeutic management, including limb-sparing surgeries and dose-intense systemic chemotherapies, 30-40% of patients will experience progressive metastatic disease within 5 years of diagnosis. In order to reduce the fatality rate associated with recurrent or metastatic OS, a more thorough understanding of OS pathogenesis and biology is required. Towards this pursuit, comparative animal models of OS have been developed and are actively being studied to expand our fundamental understanding of OS. It is anticipated that specific animal models of OS, which most accurately recapitulate the natural disease process in people, will be most useful for advancing our understanding of OS biology, and will facilitate the discovery of disease pathogenesis and the identification of novel therapeutic strategies for managing this lethal metastatic bone sarcoma.

Entities:  

Mesh:

Year:  2010        PMID: 20735317     DOI: 10.1586/era.10.107

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  12 in total

Review 1.  A review of the association between osteosarcoma metastasis and protein translation.

Authors:  T S Osborne; C Khanna
Journal:  J Comp Pathol       Date:  2012-01-31       Impact factor: 1.311

2.  Inhibition of M2-like macrophages by all-trans retinoic acid prevents cancer initiation and stemness in osteosarcoma cells.

Authors:  Xue-Jing Shao; Sen-Feng Xiang; Ying-Qian Chen; Ning Zhang; Ji Cao; Hong Zhu; Bo Yang; Qian Zhou; Mei-Dan Ying; Qiao-Jun He
Journal:  Acta Pharmacol Sin       Date:  2019-07-11       Impact factor: 6.150

3.  Does rarity mean imparity? Biological characteristics of osteosarcoma cells originating from the spine.

Authors:  Zhenhua Zhou; Yan Li; Xu Yan; Xudong Wang; Cheng Yang; Haifeng Wei; Xinghai Yang; Jianru Xiao
Journal:  J Cancer Res Clin Oncol       Date:  2017-05-27       Impact factor: 4.553

4.  Establishment and characterization of a new highly metastatic human osteosarcoma cell line derived from Saos2.

Authors:  Lin Du; Qiming Fan; Bing Tu; Wei Yan; Tingting Tang
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

5.  A clinically relevant mouse model of canine osteosarcoma with spontaneous metastasis.

Authors:  Beth K Chaffee; Matthew J Allen
Journal:  In Vivo       Date:  2013 Sep-Oct       Impact factor: 2.155

6.  Osteocytes serve as a progenitor cell of osteosarcoma.

Authors:  Joseph L Sottnik; Brittany Campbell; Rohit Mehra; Omid Behbahani-Nejad; Christopher L Hall; Evan T Keller
Journal:  J Cell Biochem       Date:  2014-08       Impact factor: 4.429

7.  Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma.

Authors:  Vaibhav Saini; Curtis D Hose; Anne Monks; Kunio Nagashima; Bingnan Han; Dianne L Newton; Angelena Millione; Jalpa Shah; Melinda G Hollingshead; Karen M Hite; Mark W Burkett; Rene M Delosh; Thomas E Silvers; Dominic A Scudiero; Robert H Shoemaker
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

8.  Global gene expression analysis of canine osteosarcoma stem cells reveals a novel role for COX-2 in tumour initiation.

Authors:  Lisa Y Pang; Emma L Gatenby; Ayako Kamida; Bruce A Whitelaw; Ted R Hupp; David J Argyle
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

9.  Genetically engineered mouse models and human osteosarcoma.

Authors:  Alvin Jm Ng; Anthony J Mutsaers; Emma K Baker; Carl R Walkley
Journal:  Clin Sarcoma Res       Date:  2012-10-04

10.  Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma.

Authors:  Diana Yu; Elliot Kahen; Christopher L Cubitt; Jeremy McGuire; Jenny Kreahling; Jae Lee; Soner Altiok; Conor C Lynch; Daniel M Sullivan; Damon R Reed
Journal:  Sci Rep       Date:  2015-11-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.